Revenue: As of FY2025 Q3, the actual value is USD 0.EPS: As of FY2025 Q3, the actual value is USD -0.06.EBIT: As of FY2025 Q3, the actual value is USD -4.086 M.<h3>Financial Results for September 30, 2025</h3><ul><li>Net Loss: The company reported a net loss of approximately $4.0 million, or $0.06 per share, for the three months ended September 30, 2025, compared to a net loss of approximately $8.4 million, or $0.25 per share, for the same period in 2024.</li><li>Cash and Cash Equivalents: As of September 30, 2025, the company’s cash and cash equivalents totaled approximately $13.2 million, compared to approximately $13.5 million as of December 31, 2024.</li><li>Operating Expenses: Total operating expenses for the three months ended September 30, 2025, were $4,029,841, compared to $8,462,534 for the same period in 2024.</li><li>Loss from Operations: The loss from operations was - $4,029,841 for the three months ended September 30, 2025, compared to - $8,462,534 for the same period in 2024.</li><li>Total Assets: Total assets as of September 30, 2025, were $14,332,649, compared to $15,503,088 as of December 31, 2024.</li><li>Total Liabilities: Total liabilities as of September 30, 2025, were $9,782,914, compared to $14,690,516 as of December 31, 2024.</li></ul><h3>Outlook / Guidance</h3><ul><li>Reviva Pharmaceuticals Holdings, Inc. plans to have a pre-NDA meeting with the FDA in Q4 2025 to discuss the path to approval for brilaroxazine for schizophrenia, with a potential NDA submission targeted for Q2 2026. The company is also pursuing partnership opportunities for the development of its pipeline.</li></ul>

Reviva Pharmaceuticals | 8-K: FY2025 Q3 Revenue: USD 0